Published in Epilepsia on January 01, 2002
Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol (2006) 1.74
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Brain tumor-related epilepsy. Curr Neuropharmacol (2012) 0.96
Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. Br J Clin Pharmacol (2005) 0.83
Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals (Basel) (2012) 0.79
Managing depressive disorders in patients with epilepsy. Psychiatry (Edgmont) (2007) 0.77
Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. Br J Clin Pharmacol (2008) 0.75
Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions. Int Clin Psychopharmacol (2014) 0.75
Specialist management of routine dental procedures in adults with refractory epilepsy. Br Dent J (2014) 0.75
Effect of carbamazepine or phenytoin therapy on blood level of intravenously administered midazolam: a prospective cohort study. J Anesth (2015) 0.75
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2009) 7.03
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol (2011) 3.93
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 3.69
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (2008) 2.74
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia (2013) 1.82
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol (2003) 1.76
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol (2009) 1.73
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69
Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56
Vigabatrin and epilepsy: lessons learned. Epilepsia (2007) 1.55
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia (2009) 1.38
Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009. Epilepsia (2010) 1.37
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res (2006) 1.30
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res (2006) 1.23
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia (2007) 1.23
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol (2003) 1.20
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia (2011) 1.20
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia (2002) 1.17
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia (2004) 1.16
Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol (2009) 1.10
EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 1.07
Revisiting phenobarbital for epilepsy. BMJ (2004) 1.07
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia (2013) 1.07
Epilepsy after head injury. Curr Opin Neurol (2004) 1.06
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res (2004) 1.05
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04
Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res (2003) 1.01
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia (2010) 0.99
New and forthcoming anti-epileptic drugs. Curr Opin Neurol (2011) 0.97
Treatment of epilepsy in developing countries. BMJ (2007) 0.94
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94
Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia (2014) 0.93
Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia (2014) 0.91
Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res (2010) 0.90
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol (2005) 0.90
The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res (2006) 0.88
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia (2006) 0.87
Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res (2004) 0.87
Novel medications for epilepsy. Drugs (2011) 0.86
Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol (2009) 0.86
Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs (2009) 0.86
Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.86
The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia (2014) 0.86
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol (2002) 0.86
Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet (2013) 0.85
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. Ther Drug Monit (2008) 0.84
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia (2011) 0.84
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia (2005) 0.84
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit (2006) 0.84
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit (2003) 0.84
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res (2005) 0.83
Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia (2006) 0.83
Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet (2005) 0.83
Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat (2008) 0.83
Commentary: Epilepsy is a Global Problem. Epilepsia (2014) 0.83
A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia (2011) 0.83
Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia (2006) 0.83
Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia (2003) 0.82
Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs (2009) 0.82
Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Res (2007) 0.82
Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. Epilepsia (2009) 0.81
Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit (2003) 0.81
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia (2005) 0.81
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit (2002) 0.81
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. Expert Rev Neurother (2013) 0.80
Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience. Epileptic Disord (2006) 0.80
Pharmacology of antiepileptic drugs during pregnancy and lactation. Epilepsy Behav (2007) 0.80
When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy? Lancet Neurol (2010) 0.80
Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. Epilepsy Res (2011) 0.80
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab Toxicol (2015) 0.80
Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: reply to Costa et al. Epilepsia (2011) 0.79
The Written Declaration on Epilepsy: an important achievement for Europe and beyond. Seizure (2011) 0.78
Translating monotherapy trials into clinical practice: a look into the abyss. Epilepsy Behav (2003) 0.78
Preclinical activity profile of α-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Res (2011) 0.78
Addressing overtreatment in patients with refractory epilepsy at a tertiary referral centre in Brazil. Epileptic Disord (2011) 0.78
Old versus new antiepileptic drugs: the SANAD study. Lancet (2007) 0.77
NICE guidance on newer drugs for epilepsy in adults. BMJ (2004) 0.77
The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter? CNS Drugs (2011) 0.77
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 0.76
Italian consensus conference on epilepsy and pregnancy, labor and puerperium. Epilepsia (2009) 0.76
Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy. CNS Drugs (2014) 0.76
Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. Epilepsia (2010) 0.76
Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia (2003) 0.76
Epilepsy in elderly people: management issues. Epileptic Disord (2002) 0.76
The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Res (2012) 0.76
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. Anal Bioanal Chem (2011) 0.76
Major birth defects after exposure to newer-generation antiepileptic drugs. JAMA (2011) 0.75
The International League Against Epilepsy at the threshold of its second century: year 2. Epilepsia (2012) 0.75
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma. Ther Drug Monit (2007) 0.75
The International League Against Epilepsy at the threshold of its second century: year 1. Epilepsia (2011) 0.75